Biolex reports additional Locteron data

Biolex Therapeutics Inc. (Pittsboro, N.C.) reported additional data from the Phase IIb SELECT-2 trial of Locteron to treat HCV genotype 1 infection in 116 interferon-naive patients. A greater proportion of patients receiving 320, 480 and 640 ug twice-weekly subcutaneous Locteron achieved a sustained virologic response (SVR) 12 weeks after the end of the 48-week treatment period vs. PEG-Intron peginterferon alfa-2b (36%, 35% and 45%, respectively, vs. 30%). All doses of Locteron also led to significant reductions in flu-like adverse events compared to PEG-Intron (p<0.001). The trial's primary endpoint is the proportion of patients achieving a SVR 24 weeks after the end of treatment. ...